Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 24 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-1.15 Insider Own2.14% Shs Outstand17.15M Perf Week-15.26%
Market Cap6.32M Forward P/E- EPS next Y-0.76 Insider Trans0.00% Shs Float16.78M Perf Month-25.35%
Income-18.35M PEG- EPS next Q-0.19 Inst Own6.14% Short Float2.35% Perf Quarter-16.94%
Sales0.00M P/S- EPS this Y28.95% Inst Trans-1.30% Short Ratio2.92 Perf Half Y-16.79%
Book/sh2.16 P/B0.17 EPS next Y6.17% ROA-27.14% Short Interest0.39M Perf Year-45.79%
Cash/sh1.35 P/C0.27 EPS next 5Y- ROE-38.93% 52W Range0.20 - 1.20 Perf YTD-14.30%
Dividend Est.- P/FCF- EPS past 5Y51.06% ROI-44.43% 52W High-69.28% Beta1.50
Dividend TTM- Quick Ratio4.07 Sales past 5Y0.00% Gross Margin- 52W Low86.92% ATR (14)0.03
Dividend Ex-Date- Current Ratio4.07 EPS Y/Y TTM12.33% Oper. Margin0.00% RSI (14)34.64 Volatility7.67% 6.68%
Employees22 Debt/Eq0.05 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price2.00
Option/ShortNo / Yes LT Debt/Eq0.04 EPS Q/Q9.99% Payout- Rel Volume0.89 Prev Close0.38
Sales Surprise- EPS Surprise24.39% Sales Q/Q- EarningsMar 25 BMO Avg Volume134.97K Price0.37
SMA20-16.10% SMA50-20.36% SMA200-27.53% Trades Volume122,599 Change-2.20%
Apr-23-24 07:00AM
Apr-22-24 04:35PM
Apr-08-24 08:00AM
Mar-26-24 08:42AM
Mar-25-24 10:38PM
07:30AM Loading…
Mar-19-24 08:00AM
Mar-11-24 08:00AM
Feb-07-24 08:00AM
Jan-16-24 08:00AM
Dec-05-23 07:00AM
Nov-20-23 05:56PM
Nov-14-23 03:14AM
Nov-13-23 08:15AM
04:05PM Loading…
Nov-06-23 04:05PM
Nov-02-23 04:15PM
Nov-01-23 07:00AM
Oct-23-23 07:00AM
Oct-16-23 08:00AM
Oct-04-23 07:00AM
Sep-28-23 08:00AM
Aug-08-23 10:43PM
Aug-02-23 07:00AM
Aug-01-23 04:05PM
Jun-27-23 04:10PM
May-23-23 08:00AM
10:22PM Loading…
May-11-23 10:22PM
May-04-23 08:00AM
Apr-13-23 08:00AM
Mar-30-23 08:00AM
Mar-24-23 04:05PM
Mar-20-23 08:00AM
Feb-16-23 12:05PM
Jan-17-23 04:05PM
Jan-09-23 08:00AM
Dec-06-22 07:00AM
Dec-01-22 08:00AM
Nov-10-22 04:45PM
Nov-03-22 04:05PM
Oct-31-22 08:00AM
Oct-24-22 08:00AM
Theriva Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. Its product portfolio includes SYN-020 and SYN-004. SYN-020 is intended to prevent the antibiotic-mediated microbiome damage, C. difficile infections (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR) and acute graft-versus-host disease (aGVHD) in allogeneic HCT recipients. SYN-004 is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antimicrobial resistance. The company was founded by Steven H. Kanzer in January 2001 and is headquartered in Rockville, MD.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SHALLCROSS STEVEN ACEO and CFOJun 07 '23Buy0.6914,0009,703250,000Jun 08 07:00 AM
SHALLCROSS STEVEN ACEO and CFOJun 06 '23Buy0.6326,00016,453236,000Jun 07 07:00 AM